source
- Solstice Oncology secures $225M Series A to advance CTLA-4 antibody porustobart in colon cancerSolstice Oncology, a biotech startup focused on immunotherapy, announced it has raised $225 million in a Series A financing round. The funding will support development of its lead candidate, a CTL…
- Tyra Biosciences reports phase 2 bladder cancer data, complete response rates miss analyst targets, shares slideTyra Biosciences disclosed early phase 2 results for its FGFR3‑selective inhibitor dabogratinib in patients with low‑grade, intermediate‑risk non‑muscle‑invasive bladder cancer. The trial evaluate…